Physician profile
Milly M Mui
NPI 1841429941
$45,863.93
in general payments reported to CMS, 2019-2025
30 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,467 · 2020: $1,429 · 2021: $2,545 · 2022: $3,189 · 2023: $2,865 · 2024: $3,847 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $20K · Food and Beverage: $12K · Travel and Lodging: $2,989 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,900.00 |
| Food and Beverage | $12,327.41 |
| Travel and Lodging | $2,989.47 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $28,155.82 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $2,835.11 | 2019-2025 | Precision 1, Rocklatan, Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,645.79 | 2019-2021 | |
| Allergan, INC. | $1,517.17 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $1,365.12 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $1,036.63 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $1,019.65 | 2020-2021 | |
| Oyster Point Pharma, INC. | $992.41 | 2022-2023 | Tyrvaya |
| Abbvie INC. | $923.10 | 2022-2025 | |
| Coopervision INC. | $877.71 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $790.05 | 2022-2025 | Acuvue |
| Shire North American Group INC | $547.56 | 2019 | |
| Horizon Therapeutics Plc | $526.73 | 2022-2023 | Tepezza |
| Amgen INC. | $521.00 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $404.32 | 2024-2025 | Vevye |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $390.33 | 2020-2022 | |
| Dompe US, INC. | $381.66 | 2022-2025 | Oxervate |
| Sight Sciences, INC. | $357.56 | 2022-2023 | Tearcare System |
| Biotissue Holdings INC. | $246.01 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $241.16 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $228.00 | 2019 | |
| Topcon Healthcare, INC. | $181.45 | 2025 | |
| Rxsight INC | $147.20 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Eyepoint US, INC. | $143.26 | 2022 | |
| Astellas Pharma US INC | $131.02 | 2025 | Izervay |
| Glaukos Corporation | $105.93 | 2022 | |
| Kala Pharmaceuticals, INC. | $92.79 | 2021 | |
| Thea Pharma INC. | $22.75 | 2025 | Iyuzeh |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milly Mui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.